Wells Fargo & Company Pro Qr Therapeutics N.V. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Wells Fargo & Company holds 10,996 shares of PRQR stock, worth $20,672. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,996
Previous 10,996
-0.0%
Holding current value
$20,672
Previous $25,000
28.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PRQR
# of Institutions
52Shares Held
17.2MCall Options Held
26.2KPut Options Held
8.6K-
Privium Fund Management B.V.5.58MShares$10.5 Million2.62% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.63MShares$6.82 Million0.01% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA2.04MShares$3.84 Million0.12% of portfolio
-
M28 Capital Management LP Stamford, CT1.02MShares$1.92 Million1.95% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA906KShares$1.7 Million0.39% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $134M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...